[
  {
    "symbol": "VERA",
    "timestamp": "2024-12-12 16:53:54",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's\u00a0product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/dmVyYXR4LmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/dmVyYXR4LmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "price": 45.11,
    "priceChange": -2.905725355144213,
    "openPrice": 46.5,
    "prevClose": 46.46,
    "dayHigh": 47.04,
    "dayLow": 44.54,
    "volume": 449150,
    "prevVolume": 377555,
    "volumeMetrics": {
      "recentVolumes": [
        313058,
        289795,
        370527,
        377555,
        449150
      ],
      "volumeDates": [
        "2024-12-05",
        "2024-12-08",
        "2024-12-09",
        "2024-12-10",
        "2024-12-11"
      ],
      "dailyChanges": [
        -7.43,
        27.86,
        1.9,
        18.96
      ],
      "averageVolume": 745775.984375,
      "volumeChange": 18.96,
      "volumeVsAvg": -39.77
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 745775.984375
    },
    "marketCap": 2856502920.83,
    "insiderActivity": {
      "recent_trades": 13,
      "net_shares": 21524,
      "notable_trades": [
        {
          "date": "2024-11-25",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 19375,
          "value": 929560.0,
          "price_per_share": 47.97729032258064
        },
        {
          "date": "2024-11-13",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 30625,
          "value": 1516037.0,
          "price_per_share": 49.50324897959184
        },
        {
          "date": "2024-10-28",
          "insider": "SEIDENBERG BETH C",
          "position": "Director",
          "type": "Sale",
          "shares": 15000,
          "value": 720493.0,
          "price_per_share": 48.03286666666666
        },
        {
          "date": "2024-10-23",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 19375,
          "value": 782610.0,
          "price_per_share": 40.392774193548384
        },
        {
          "date": "2024-10-09",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 15625,
          "value": 597568.0,
          "price_per_share": 38.244352
        },
        {
          "date": "2024-09-25",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 23125,
          "value": 1064809.0,
          "price_per_share": 46.0457945945946
        },
        {
          "date": "2024-09-19",
          "insider": "SEIDENBERG BETH C",
          "position": "Director",
          "type": "Sale",
          "shares": 16476,
          "value": 696233.0,
          "price_per_share": 42.25740470988104
        }
      ],
      "summary": {
        "total_sales": 139601,
        "total_purchases": 53000,
        "total_awards": 108125,
        "sales_count": 7,
        "purchases_count": 1,
        "awards_count": 5,
        "total_value": {
          "sales": 6307310.0,
          "purchases": 0.0,
          "awards": 313216.0
        }
      },
      "latest_date": "2024-11-25"
    },
    "recentNews": [
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-09T23:29:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/09/2994136/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-28T21:37:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/28/2970400/0/en/Vera-Therapeutics-Announces-Proposed-Public-Offering-of-Class-A-Common-Stock.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-26T23:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/26/2969705/0/en/Vera-Therapeutics-Announces-96-week-eGFR-Stabilization-in-ORIGIN-Phase-2b-Study-of-Atacicept-in-IgAN-in-a-Late-Breaking-Oral-Presentation-at-the-American-Society-of-Nephrology-Kidn.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-07-05T20:31:33Z",
        "url": "https://www.globenewswire.com/news-release/2024/07/05/2909190/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Appoints Christy J. Oliger to Board of Directors",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-11T20:01:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/11/2897152/0/en/Vera-Therapeutics-Appoints-Christy-J-Oliger-to-Board-of-Directors.html",
        "type": "VERA"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -16.29726
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": 0,
        "netIncome": -46632000.0,
        "researchAndDevelopment": 40314000.0,
        "operatingExpense": 49801000.0
      },
      "detailedQuarterly": {
        "revenue": [
          0.0,
          0.0,
          0.0,
          0.0,
          0.0,
          NaN
        ],
        "revenueChanges": [
          null,
          NaN,
          null,
          null,
          null,
          null
        ],
        "netIncome": [
          -46632000.0,
          -33708000.0,
          -28383000.0,
          -25655000.0,
          -20104000.0,
          NaN
        ],
        "netIncomeChanges": [
          -131.95,
          NaN,
          null,
          null,
          null,
          null
        ],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": [
          "2024-09-30",
          "2024-06-30",
          "2024-03-31",
          "2023-12-31",
          "2023-09-30",
          "2023-06-30"
        ]
      }
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": false
    }
  }
]